For the quarter ending 2025-12-31, ANEB had -$1,313,203 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | -1,999,397 | -2,158,354 | -8,484,763 |
| Stock-based compensation | 198,530 | 237,644 | 1,446,824 |
| Amortization of loan commitment fee | 17,439 | 17,440 | 382,014 |
| Grant receivable | -46,958 | 63,393 | -73,218 |
| Prepaid expenses | 4,642 | -90,668 | -152,351 |
| Accounts payable | -52,677 | 383,364 | 67,749 |
| Accrued expenses | 574,502 | 92,769 | 159,356 |
| Net cash used in operating activities | -1,313,203 | -1,273,076 | -6,349,687 |
| Proceeds from issuance of common stock | - | - | 15,000,000 |
| Payment of financing/offering costs | - | - | 116,664 |
| Net cash provided by (used in) financing activities | - | - | 14,883,336 |
| Net (decrease) increase in cash | -1,313,203 | -1,273,076 | 8,533,649 |
| Cash and cash equivalents at beginning of period | 10,354,773 | 11,627,849 | 3,094,200 |
| Cash and cash equivalents at end of period | 9,041,570 | 10,354,773 | 11,627,849 |
Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc. (ANEB)